High-dose 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial.


Journal Article

This Phase I trial explores the use of high-dose 90Y conjugated to the antibreast cancer monoclonal antibody BrE-3 and autologous hematologic cell support in the treatment of women with stage four breast cancer. Nine women with heavily pretreated disease were enrolled. All of the patients had BrE-3-positive tumors by immunostaining and were treated with increasing doses of 90Y (15 mCi/m2, 3 patients), 20 mCi/M2 (six patients), and a fixed (50 mg) dose of BrE-3. 111In-labeled BrE-3 (5 mCi) was given simultaneously for scanning purposes. The only toxicity noted was hematological. Grade 4 platelet toxicity requiring transfusion support occurred in four patients. Grade 4 WBC toxicity was seen in two patients that resolved in 3-9 days. All hematological nadirs occurred approximately 25 days after treatment. Objective partial responses were noted in 4 of 8 (50%) patients with measurable tumors. Dose escalation is ongoing.

Full Text

Duke Authors

Cited Authors

  • Schrier, DM; Stemmer, SM; Johnson, T; Kasliwal, R; Lear, J; Matthes, S; Taffs, S; Dufton, C; Glenn, SD; Butchko, G

Published Date

  • December 1, 1995

Published In

Volume / Issue

  • 55 / 23 Suppl

Start / End Page

  • 5921s - 5924s

PubMed ID

  • 7493371

Pubmed Central ID

  • 7493371

International Standard Serial Number (ISSN)

  • 0008-5472


  • eng

Conference Location

  • United States